Healthcare -
Biotechnology - NASDAQ - US
$ 2.53
-7.66 %
$ 153 M
Market Cap
-2.06
P/E
1. INTRINSIC VALUE
Balance Sheet
Rezolute, Inc.
| Current Assets | 129 M |
| Cash & Short-Term Investments | 127 M |
| Receivables | 0 |
| Other Current Assets | 1.78 M |
| Non-Current Assets | 4.08 M |
| Long-Term Investments | 263 K |
| PP&E | 1.98 M |
| Other Non-Current Assets | 1.84 M |
| Current Liabilities | 9.61 M |
| Accounts Payable | 4.9 M |
| Short-Term Debt | 568 K |
| Other Current Liabilities | 4.14 M |
| Non-Current Liabilities | 2.13 M |
| Long-Term Debt | 1.66 M |
| Other Non-Current Liabilities | 468 K |
EFFICIENCY
Earnings Waterfall
Rezolute, Inc.
| Revenue | 0 |
| Cost Of Revenue | 36 K |
| Gross Profit | -36 K |
| Operating Expenses | 70.4 M |
| Operating Income | -70.4 M |
| Other Expenses | -1.96 M |
| Net Income | -68.5 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Rezolute, Inc.
| Net Income | -68.5 M |
| Depreciation & Amortization | 36 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 7.36 M |
| Change in Working Capital | 3.1 M |
| Others | 2.61 M |
| Free Cash Flow | -57.4 M |
Wall Street Analysts Price Targets
Rezolute, Inc.
Wall Street analysts predict an average 1-year price target for RZLT of $13.5 , with forecasts ranging from
a
low of
$11 to a high of $15 .
RZLT Lowest Price Target
Wall Street Target
11 USD
334.78%
RZLT Average Price Target
Wall Street Target
13.5 USD
433.60%
RZLT Highest Price Target
Wall Street Target
15 USD
492.89%
4. DIVIDEND
ANALYSIS
RZLT does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Rezolute, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
47 K USD 1
0-3 MONTHS
84.3 K USD 1
3-6 MONTHS
20 K USD 1
6-9 MONTHS
5.24 M USD 4
9-12 MONTHS
7. News
Rezolute: Late-Stage Study Targeting Hyperinsulinism
Rezolute is a microcap biopharma focused on developing therapies for hypoglycemia caused by hyperinsulinism, with promising late-stage trials for RZ358 and RZ402. RZ358 targets Congenital Hyperinsulinism and Tumor Hyperinsulinism, showing significant efficacy in reducing hypoglycemia in phase 2 trials. Financially, RZLT has a market cap of $279mn, $105mn in cash, and a cash runway of 5–7 quarters, with manageable expenses.
seekingalpha.com
- 1 month ago
Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), receives Breakthrough Therapy Designation and Orphan Drug Designation
globenewswire.com
- 1 month ago
RZLT Shares Rise 30.8% in 6 Months: What's Driving the Rally?
Rezolute rides on robust clinical development activity for lead candidate ersodetug (RZ358) for treating hypoglycemia caused by hyperinsulinism.
zacks.com
- 1 month ago
Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Open-label arm (infant participants < 1 year old) has been recently reviewed by a Data Monitoring Committee (DMC) and target drug concentrations were safely reached at tested doses
globenewswire.com
- 2 months ago
Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference
REDWOOD CITY, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, today announced that management will participate in the Guggenheim SMID Cap Biotech Conference, taking place February 5-6, 2025, in New York City.
globenewswire.com
- 2 months ago
Here's Why 'Trend' Investors Would Love Betting on Rezolute (RZLT)
If you are looking for stocks that are well positioned to maintain their recent uptrend, Rezolute (RZLT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
zacks.com
- 2 months ago
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
We present three small biotech stocks, which according to Wall Street analysts, have upside potential for 2025.
zacks.com
- 3 months ago
Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, today announced that its compensation committee has approved the issuance of One Hundred and Fifty Thousand (150,000) shares of its common stock as an inducement award (the “Inducement Award”) permitted under Nasdaq Rule 5635(c)(4) to its new Senior Vice President of Global Product Supply. The Inducement Award was granted on November 30, 2024 and was priced at our closing price on November 29, 2024. The Inducement Award will vest 25% one year after the executive's start date and will vest monthly for 36 months after.
globenewswire.com
- 4 months ago
RZLT Stock Rises on FDA's Orphan Designation for Rare Disease Drug
The FDA bestows an Orphan Drug status to Rezolute's ersodetug for treating hypoglycemia due to tumor hyperinsulinism. Shares rise.
zacks.com
- 4 months ago
Rezolute: Ersodetug Downstream Tech Could Ignite The Hyperinsulinism Market
Rezolute, Inc. expects to report top-line results from the phase 3 sunRIZE study using ersodetug + placebo to treat patients with Congenital Hyperinsulinism in the 2nd half of 2025. The global Congenital Hyperinsulinism treatment market is estimated to be worth $327.8 million by 2032; the Company believes that cHI and tHI could both generate sales >$1 billion. A phase 3 registrational study, using ersodetug for patients with Tumor Hyperinsulinism expected to start in the 1st half of 2025 and release top-line data from it 2nd half of 2026.
seekingalpha.com
- 4 months ago
Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update
FDA lifts partial clinical holds on ersodetug for the treatment of congenital HI; Phase 3 sunRIZE study to proceed in the U.S.
globenewswire.com
- 6 months ago
RZLT Stock Up as FDA Lifts Clinical Holds on Rare Disease Study
The FDA removes the partial clinical holds on Rezolute's phase III study evaluating RZ358 for treating congenital hyperinsulinism.
zacks.com
- 6 months ago
8. Profile
Summary
Rezolute, Inc. RZLT
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 153 M
Dividend Yield
0.00%
Description
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Contact
201 Redwood Shores Parkway, Redwood City, CA, 94065
https://www.rezolutebio.com
IPO
Date
Jan. 14, 2013
Employees
64
Officers
Mr. Daron G. Evans M.B.A., M.S.
Chief Financial Officer
Dr. Brian Kenneth Roberts M.D.
Chief Medical Officer
Mr. Nevan Charles Elam J.D.
Founder, Chief Executive Officer, Principal Financial Officer & Acting Chairman of the Board
Mr. Michael R. Deperro
Senior Vice President & Head of Corporate Development
Mr. Chris Milks
Vice President & Head of Finance
Dr. Raj Agrawal M.D.
Vice President & Head of Ophthalmological Clinical Development
Dr. Davelyn Eaves Hood M.B.A., M.D.
Director and Head of Scientific & Patient Affairs
Mr. Michael Covarrubias
Senior Vice President & Head of Program & Portfolio Management
Ms. Robyn Sweinhart
Vice President & Head of Quality
Ms. Erin O'Boyle
Senior Vice President & Head of Clinical Operations